The sample copy of this report is available for access.
“Global Human Milk Oligosaccharides Market to reach a market value of USD 891.2 Million by 2033 growing at a CAGR of 11.3%”
The Global Human Milk Oligosaccharides Market is expected to reach USD 891.2 million by 2033, growing at a CAGR of 11.3% during 2026 - 2033.
The Human Milk Oligosaccharides (HMO) Market originated from the recognition of HMOs as one of the most important bioactive components present in human breast milk. Advances in microbial fermentation, enzymatic synthesis, and biotechnology have enabled large-scale commercial production of HMOs, facilitating their incorporation into infant formula, dietary supplements, functional foods, and pharmaceutical products. The market is witnessing strong growth due to increasing awareness regarding infant nutrition, expanding applications in gut health and immune support, and growing scientific validation of HMO functionality. Manufacturers continue to invest in advanced production technologies, regulatory approvals, and product innovation to expand the commercialization of HMOs globally.
Today, HMOs have evolved from niche research ingredients into mainstream nutritional components utilized across infant nutrition and emerging adult health applications. The market continues to benefit from technological advancements in microbial fermentation, increasing clinical validation of health benefits, growing regulatory support, and expanding demand for premium nutritional products. Companies are increasingly focusing on diversified HMO portfolios, advanced formulation capabilities, and geographically targeted expansion strategies to strengthen their competitive positions.
The major strategies followed by market participants are Product Expansion, Regulatory Approvals, Strategic Partnerships, Geographical Expansion, Fermentation Technology Innovation, Production Scale-Up, and Portfolio Diversification. Leading companies continue investing in advanced fermentation technologies, new HMO approvals, global commercialization initiatives, and expanded application development across infant nutrition and health-focused product categories.
Based on Application, the Human Milk Oligosaccharides Market is segmented into Infant Formula, Dietary Supplements, Food & Beverages, and Pharmaceuticals.
The Infant Formula market dominated the Global Human Milk Oligosaccharides Market by Application in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 673.5 million by 2033, growing at a CAGR of 10.9 % during the forecast period. The Dietary Supplements market is expected to witness a CAGR of 11.9% during (2026 - 2033).
The Infant Formula segment emerged as the leading application segment in the Human Milk Oligosaccharides Market in 2025. The growth of this segment is driven by increasing demand for advanced infant nutrition products that closely mimic the composition and functional benefits of human breast milk. Infant formula manufacturers are increasingly incorporating HMOs into formulations to support immune system development, improve gut microbiota balance, and enhance overall infant health outcomes.
Based on Type, the Human Milk Oligosaccharides Market is segmented into 2’FL, LNnT, 3’FL, 6’SL, 3’SL, LNT, and DFL.
The 2’FL market dominated the Global Human Milk Oligosaccharides Market by Type in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 354.1 million by 2033, growing at a CAGR of 10.1 % during the forecast period. The LNnT market is expected to witness a CAGR of 10.3% during (2026 - 2033).
The 2’FL segment emerged as the leading type segment in the Human Milk Oligosaccharides Market in 2025. The growth of this segment is driven by its extensive utilization in infant nutrition products and strong scientific validation regarding digestive and immune health benefits. Manufacturers increasingly utilize 2’FL to improve formula functionality, support gut microbiome development, and enhance infant immune system maturation. Growing clinical evidence and regulatory acceptance continue to strengthen demand globally.
Free Valuable Insights: Human Milk Oligosaccharides Market Size to reach $891.2 Million by 2033
Based on Region, the Human Milk Oligosaccharides Market is segmented into North America, Europe, Asia Pacific, and LAMEA.
The North America market dominated the Global Human Milk Oligosaccharides Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 298.2 million by 2033, growing at a CAGR of 10.7 % during the forecast period.The Asia Pacific market is expected to witness a CAGR of 11.9% during (2026 - 2033).
The North America market emerged as the leading regional market in the Human Milk Oligosaccharides Market in 2025. The growth of this regional market is driven by strong adoption of premium infant nutrition products, increasing consumer awareness regarding infant health, and substantial investments in nutritional science research.
Human Milk Oligosaccharides Market Coverage
| Report Attribute | Details |
|---|---|
| Market size value in 2026 | USD 421.3 Million |
| Market size forecast in 2033 | USD 891.2 Million |
| Base Year | 2025 |
| Historical Period | 2022 to 2024 |
| Forecast Period | 2026 to 2033 |
| Revenue Growth Rate | CAGR of 11.3% from 2026 to 2033 |
| Number of Pages | 553 |
| Tables | 630 |
| Report Coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Market Share Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Value Chain Analysis, Product Life Cycle Analysis, Market Consolidation Analysis, Key Customer Criteria, Winning Imperatives |
| Segments Covered | Application, Type, Region |
| Country Scope |
|
| Companies Included | DSM-Firmenich AG; International Flavors & Fragrances Inc.; BASF SE; Abbott Laboratories; Nestlé S.A.; FrieslandCampina C.V.; Novonesis A/S; Inbiose NV; KYOWA HAKKO BIO Co., Ltd. (Kirin Holdings Co., Ltd.); ELICITYL S.A. |
By Application
By Type
By Geography
Expected to reach USD 891.2 Million by 2033, growing at a CAGR of 11.3% during 2026-2033.
Infant Formula leads, achieving USD 673.5 Million by 2033.
DSM-Firmenich AG, International Flavors & Fragrances Inc., BASF SE, Abbott Laboratories, Nestlé S.A., FrieslandCampina C.V.
2’FL (2’-Fucosyllactose) leads, reaching USD 354.1 Million by 2033.
Advancements in precision synthesis technologies and rising consumer awareness of infant gut health.
The market grows at a CAGR of 11.3% during the forecast period (2026-2033).
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 